Jaguar Health Details Executive Equity Awards, Compensation Structure

Ticker: JAGX · Form: DEF 14A · Filed: 2025-07-21T00:00:00.000Z

Sentiment: neutral

Topics: Executive Compensation, Equity Awards, DEF 14A, Shareholder Dilution, Corporate Governance, Pharmaceuticals, SEC Filing

Related Tickers: JAGX

TL;DR

**JAGX's executive compensation is heavily tied to equity, signaling a long-term focus but watch for potential dilution.**

AI Summary

Jaguar Health, Inc. (JAGX) filed its DEF 14A on July 21, 2025, outlining executive compensation and governance matters for the fiscal year ended December 31, 2024. The filing details equity awards granted and vested for both named executive officers (PEO) and non-PEO executives, as well as changes in fair value of outstanding awards. For the 2022 fiscal year, the fair value of equity awards granted and vested for PEOs was reported, alongside adjustments excluding values reported in the summary compensation table. The company's strategic outlook, while not explicitly detailed in terms of revenue or net income figures within this specific DEF 14A, focuses on aligning executive incentives with long-term shareholder value through equity-based compensation. Risks related to executive compensation structures and potential dilution from equity awards are implicitly present. The filing also provides historical data for equity awards from 2021 to 2024, indicating a consistent approach to incentivizing leadership through stock-based compensation.

Why It Matters

This DEF 14A filing provides crucial transparency into how Jaguar Health compensates its leadership, directly impacting shareholder value through potential dilution and incentive alignment. For investors, understanding the equity award structure for PEOs and non-PEO executives from 2021 to 2024 is vital for assessing governance and future performance drivers. Employees may see this as a benchmark for internal compensation practices, while customers are indirectly affected by the company's ability to retain top talent. In the competitive pharmaceutical preparations industry, effective executive compensation is key to attracting and retaining the talent needed to drive innovation and market share.

Risk Assessment

Risk Level: medium — The filing indicates a significant reliance on equity awards for executive compensation across 2021-2024, which can lead to shareholder dilution if not managed effectively. While specific dollar amounts for dilution are not provided, the consistent granting of equity awards to both PEO and non-PEO executives suggests a continuous increase in outstanding shares, potentially impacting per-share earnings.

Analyst Insight

Investors should scrutinize Jaguar Health's future financial statements for the impact of these equity awards on share count and earnings per share. Evaluate the performance metrics tied to these awards to ensure they align with long-term shareholder value creation, and consider the potential for dilution when assessing future stock performance.

Financial Highlights

debt To Equity: 0.0
revenue: $0
operating Margin: 0%
total Assets: $0
total Debt: $0
net Income: $0
eps: $0
gross Margin: 0%
cash Position: $0
revenue Growth: 0%

Executive Compensation

Name	Title	Total Compensation
Not Disclosed	Principal Executive Officer	$0
Not Disclosed	Principal Financial Officer	$0
Not Disclosed	Other Named Executive Officers	$0

Key Numbers

2025-07-21 — Filing Date (Date the DEF 14A was filed with the SEC)
2024-12-31 — Fiscal Year End (The period covered by the executive compensation data)
2021-01-01 — Start of Equity Award Data (Beginning of the period for which equity award data is provided)
2024-12-31 — End of Equity Award Data (End of the period for which equity award data is provided)
001-36714 — SEC File Number (Unique identifier for Jaguar Health's SEC filings)

Key Players & Entities

Jaguar Health, Inc. (company) — filer of the DEF 14A
SEC (regulator) — recipient of the DEF 14A filing
001-36714 (regulatory) — SEC file number for Jaguar Health, Inc.
2025-07-21 (date) — filing date of the DEF 14A
2024-12-31 (date) — end of the fiscal year reported in the DEF 14A
200 Pine Street Suite 400 (location) — business address of Jaguar Health, Inc.
San Francisco (location) — city of Jaguar Health, Inc.'s business address
California (location) — state of Jaguar Health, Inc.'s business address
Pharmaceutical Preparations (industry) — Standard Industrial Classification for Jaguar Health, Inc.
0001585608 (regulatory) — Central Index Key (CIK) for Jaguar Health, Inc.

FAQ

What is the primary purpose of Jaguar Health's DEF 14A filing?

The primary purpose of Jaguar Health's DEF 14A filing on July 21, 2025, is to provide detailed information regarding executive compensation, specifically focusing on equity awards granted and vested for both named executive officers (PEO) and non-PEO executives for the fiscal year ended December 31, 2024.

Which fiscal year's executive compensation data is covered in Jaguar Health's DEF 14A?

Jaguar Health's DEF 14A filing covers executive compensation data for the fiscal year ended December 31, 2024, with comparative data provided for prior years, including 2021, 2022, and 2023.

What type of compensation is heavily emphasized for Jaguar Health's executives?

The DEF 14A filing indicates a heavy emphasis on equity awards for Jaguar Health's executives, including both named executive officers (PEO) and non-PEO executives, across the periods from 2021 to 2024.

What are the potential risks associated with Jaguar Health's executive compensation structure?

A potential risk associated with Jaguar Health's executive compensation structure, which heavily relies on equity awards, is shareholder dilution. The consistent granting of stock-based compensation could increase the number of outstanding shares, potentially impacting earnings per share.

When was Jaguar Health, Inc. formerly known as Jaguar Animal Health, Inc.?

Jaguar Health, Inc. was formerly known as Jaguar Animal Health, Inc. until its name change on August 30, 2013, as indicated in the DEF 14A filing.

What is Jaguar Health's Standard Industrial Classification (SIC)?

Jaguar Health, Inc.'s Standard Industrial Classification (SIC) is Pharmaceutical Preparations, under code 2834, reflecting its primary business operations.

How does the DEF 14A filing impact investors in Jaguar Health?

The DEF 14A filing impacts investors by providing transparency into executive compensation, allowing them to assess how leadership incentives align with shareholder interests and to evaluate the potential for dilution from equity awards, which can affect future stock performance.

What is the Central Index Key (CIK) for Jaguar Health, Inc.?

The Central Index Key (CIK) for Jaguar Health, Inc. is 0001585608, which is used by the SEC to identify the company's filings.

Where is Jaguar Health, Inc.'s business address located?

Jaguar Health, Inc.'s business address is located at 200 Pine Street, Suite 400, San Francisco, California, 94104.

Does the DEF 14A provide specific revenue or net income figures for Jaguar Health?

No, this specific DEF 14A filing primarily focuses on executive compensation and governance matters, detailing equity awards and their fair values, but it does not provide specific revenue or net income figures for Jaguar Health.

Risk Factors

Dilution from Equity Awards [medium — financial]: The company's reliance on equity-based compensation for executive incentives, as detailed in the DEF 14A, carries an inherent risk of shareholder dilution. While specific numbers for the current fiscal year are not detailed in this filing, historical data from 2021-2024 shows a consistent approach to granting equity awards. This practice can lead to an increase in the total number of outstanding shares, potentially reducing the earnings per share for existing shareholders if not accompanied by proportional growth in company value.
Executive Compensation Alignment [medium — operational]: The DEF 14A focuses on executive compensation structures, aiming to align incentives with long-term shareholder value. However, the effectiveness of these structures is a potential risk. If the metrics used to determine equity awards do not accurately reflect true long-term value creation or if market conditions significantly impact the value of these awards, executive incentives may not be optimally aligned, posing an operational risk to strategic execution.

Industry Context

Jaguar Health, Inc. operates within the pharmaceutical preparations industry (SIC 2834). This sector is characterized by extensive research and development, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. Companies in this space often focus on developing treatments for specific diseases, requiring significant capital investment and long development cycles.

Regulatory Implications

As a pharmaceutical company, Jaguar Health is subject to rigorous regulatory scrutiny from agencies such as the FDA. Compliance with drug development, manufacturing, and marketing regulations is paramount. Any failure to adhere to these standards can result in significant penalties, product recalls, and reputational damage, impacting the company's operations and financial performance.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Key Dates

2025-07-21: DEF 14A Filing — This filing provides detailed information on executive compensation, equity awards, and governance matters for the fiscal year ended December 31, 2024, offering insights into management's remuneration and incentives.
2024-12-31: Fiscal Year End — This date marks the end of the reporting period for the executive compensation and equity award data presented in the DEF 14A.
2021-01-01: Start of Equity Award Data — This date signifies the beginning of the historical period for which equity award data (granted, vested, and outstanding) is provided in the filing, allowing for trend analysis.
2024-12-31: End of Equity Award Data — This date marks the end of the historical period for which equity award data is presented, providing the most recent historical context for compensation practices.

Glossary

DEF 14A: A Definitive Proxy Statement filed with the SEC by public companies. It contains information about the company's annual meeting of shareholders, including details on executive compensation, board of directors, and voting matters. (This is the primary document analyzed, detailing executive compensation and governance for Jaguar Health, Inc.)
PEO: Principal Executive Officer. This is typically the Chief Executive Officer (CEO) or the highest-ranking executive officer of a company. (The filing distinguishes compensation and equity awards for the PEO, providing specific data for this key executive role.)
Equity Awards: Awards granted to employees, typically executives, in the form of company stock or stock options. These are often used as a form of compensation and incentive. (The DEF 14A extensively details the granting, vesting, and fair value of equity awards to named executive officers, highlighting their importance in executive compensation.)
Fair Value: The estimated price at which an asset would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell and both having reasonable knowledge of relevant facts. (The filing reports the fair value of equity awards granted and outstanding, which is a key metric for understanding the value of executive compensation.)
Vesting: The process by which an employee earns the right to receive or exercise an award of stock or stock options. Vesting often occurs over a period of time or upon achievement of certain performance goals. (The DEF 14A specifies which equity awards have vested, indicating when executives have earned the right to these compensation components.)

Year-Over-Year Comparison

This DEF 14A filing for the fiscal year ended December 31, 2024, continues the company's established practice of utilizing equity-based compensation for its executives, as indicated by the historical data from 2021-2024. The filing emphasizes the granting and vesting of equity awards and changes in their fair value. However, unlike filings that might show changes in revenue, net income, or specific operational risks, this document's focus is primarily on executive remuneration and governance. Therefore, a direct comparison of key financial metrics like revenue growth or margin changes to a previous filing is not possible based on the provided data, as this DEF 14A does not contain such financial performance indicators.

From the Filing

0001193125-25-161477.txt : 20250721 0001193125-25-161477.hdr.sgml : 20250721 20250721070107 ACCESSION NUMBER: 0001193125-25-161477 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250819 FILED AS OF DATE: 20250721 DATE AS OF CHANGE: 20250721 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 251135680 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 DEF 14A 1 d830050ddef14a.htm DEF 14A DEF 14A DEF 14A false 0001585608 0001585608 2024-01-01 2024-12-31 0001585608 2022-01-01 2022-12-31 0001585608 2021-01-01 2021-12-31 0001585608 2023-01-01 2023-12-31 0001585608 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:EqtyAwrdsAdjsMember ecd:PeoMember 2021-01-01 2021-12-31 0001585608 ecd:EqtyAwrdsAdjsMember ecd:NonPeoNeoMember 2021-01-01 2021-12-31 0001585608 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:EqtyAwrdsAdjsMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:EqtyAwrdsAdjsMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:PeoMember 2022-01-01 2022-12-31 0001585608 ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember ecd:NonPeoNeoMember 2022-01-01 2022-12-31 0001585608 ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember ecd:PeoMemb